RP-HPLC Method Development and Validation for the Determination of Pemigatinib using Design of Experiments Approach
Journal of Pharmaceutical Research International,
Aim: To develop and validate a simple, precise, accurate and robust RP-HPLC method for the determination of Pemigatinib by using Design of Experiments (DoE) approach.
Study Design: A 23 Factorial design consisting of three factors at two levels was considered for the experimental plan initially to select the initial chromatographic conditions and optimization was done using Box-Behnken Design. The critical method parameters selected for optimization were % Organic phase composition, pH of the buffer and flow rate. The critical quality attributes investigated were retention time, theoretical plates and tailing factor.
Methodology: Chromatographic separation was achieved on Agilent Zorbax XDB C18 (250×4.6 mm, 5 µm) column maintained at ambient temperature and PDA-UV detection set at 262nm. The optimized and predicted data from the Design Expert® (18.104.22.168) modelling software (Stat-Ease Inc., Minneapolis, MN, USA) consisted of mobile phase 0.1% OPA pH 2.5 buffer (60%): Acetonitrile (40%) pumped at a flow rate of 1.06ml/min gave the highest desirability.
Results: The retention time of the drug was found to be 3.258 min. The developed method was linear over the concentration range of 25-150 µg/mL with correlation coefficient of 0.999. The optimized method was validated as per ICH Q2 (R1) guidelines.
Conclusion: Based on the ANOVA results, the selected models for the responses retention time and tailing factor were found to be significant with P=0.05. 2D Contour plots were used to visualize the effect of factors and their interactions on the responses. Design validation was done using predicted vs. actual plots for the responses. The results of the validation parameters were within the acceptable limit. The stability of the drug was examined under different stress conditions forcibly and significant degradation was found in reductive condition.
- Design of Experiments
How to Cite
Merz V, Zecchetto C, Melisi D. Pemigatinib a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncol; 2020. DOI: 10.2217/fon-2020-0726. PMID: 33034201.
Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, Di Matteo D et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2 and 3, displays activity against genetically defined tumor models. PLoS One. 2020;15(4):e0231877. doi: 10.1371/journal.pone.0231877. PMID: 32315352; PMCID: PMC7313537. Available:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion. Available:https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf.
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R et al. Pemigatinib for previously treated, locally advanced or metastatic cholangio carcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21(5):671-684. DOI: 10.1016/S1470-2045(20)30109-1. PMID: 32203698.
Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M et al. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Ther Adv Med Oncol. 2020; 12:1758835920937889. DOI: 10.1177/1758835920937889. PMID: 32684989; PMCID: PMC7346700.
Bekaii-Saab TS, Valle JW, Eric VC , Lorenza R, Furuse J, Loka T et al. Fight-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangio carcinoma with FGFR2 rearrangements. Future Oncol. 2020;16(30):2385-2399.
Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008;76(5):965-77.
Wani TA, Ahmad A, Zargar S, Khalil NY, Darwish IA et al. Use of response surface methodology for development of new micro well-based spectrophotometric method for determination of atrovastatin calcium in tablets. Chemistry Central Journal. 2012; 6:134. Available:https://doi.org/10.1186/1752-153X-6-134.
Deepa M, Ravindra Reddy K, Satyanarayana SV. A review on quality by design approach for analytical method development. J Pharm Res 2017;11(4): 272-77.
Box GEP, Behnken DW. Some new 3 level designs for the study of quantitative variables. Technometrics 1960;2:455-75.
Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical experimental design. 1st ed. New York: Marcel Dekker; 1999.
Singh S, Singla YP, Arora S. Statistical, diagnostic and response surface analysis of nefopam hydrochloride nanospheres using 35 box-behnken design. Int J Pharm Pharm Sci. 2015;7(11):89-101.
Candioti LV, De Zan MM, Camara MS, Goicoechea HC. Experimental design and multiple response optimization using the desirability function in analytical methods development. Talanta 2014;124:123-38.
ICH Harmonised tripartite guideline: Validation of analytical procedures: Text and methodology q2 (r1), current step 4 version; international conference on harmonisation: Geneva; 2005.
ICH harmonised tripartite guideline: Stability testing of new drug substances and products Q1A (R2), current Step 4 version; International Conference on Harmonisation: Geneva; 2003.
Abstract View: 87 times
PDF Download: 71 times